Front Cover: Development of Fluorophosphoramidate as a Biocompatibly Transformable Functional Group and its Application as a Phosphate Prodrug for Nucleoside Analogs (ChemMedChem 17/2022)

The Front Cover shows a new type of biocompatible phosphate analog, a fluorophosphoramidate (FPA) functional group with characteristic P–F and P–N bonds. The stability of the FPA group was found to vary depending on the number of the amino group substitutions. Taking advantage of this intriguing mol...

Full description

Saved in:
Bibliographic Details
Published in:ChemMedChem 2022-09, Vol.17 (17), p.n/a
Main Authors: Yoshida, Yuki, Zheng, Ti, Tanabe, Wataru, Tomoike, Fumiaki, Hashiya, Fumitaka, Suzuki, Tetsuro, Hirota, Shuto, Saiki, Yuriko, Horii, Akira, Hirayama, Akiyoshi, Soga, Tomoyosi, Kimura, Yasuaki, Abe, Hiroshi
Format: Article
Language:English
Subjects:
anti-cancer drugs
antiviral drugs
nucleoside analogs
phosphate
prodrugs
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page n/a
container_issue 17
container_start_page
container_title ChemMedChem
container_volume 17
creator Yoshida, Yuki
Zheng, Ti
Tanabe, Wataru
Tomoike, Fumiaki
Hashiya, Fumitaka
Suzuki, Tetsuro
Hirota, Shuto
Saiki, Yuriko
Horii, Akira
Hirayama, Akiyoshi
Soga, Tomoyosi
Kimura, Yasuaki
Abe, Hiroshi
description The Front Cover shows a new type of biocompatible phosphate analog, a fluorophosphoramidate (FPA) functional group with characteristic P–F and P–N bonds. The stability of the FPA group was found to vary depending on the number of the amino group substitutions. Taking advantage of this intriguing molecular profile, gemcitabine FPA‐prodrug, which was designed to be efficiently converted to the corresponding monophosphate in cells, showed superior anticancer activity compared with the parent compound gemcitabine and its ProTide prodrug. More information can be found in the Research Article by Yuki Yoshida, Hiroshi Abe et al.
doi_str_mv 10.1002/cmdc.202200450
format article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_cmdc_202200450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CMDC202200450</sourcerecordid><originalsourceid>FETCH-LOGICAL-c890-2bae6009385cc7550fd4744ad11d59c811b83bad9948475742dc98d6af20b7e53</originalsourceid><addsrcrecordid>eNqFkDFPwzAQhSMEEqWwMt8IQ1s7dWqHraSkILXQoXvk2E5r5MSRnRT1t_HnSCiCkeH0Tnf3PuleENxiNMYIhRNRSjEOURgiRCJ0Fgwwm6ERxYye__Y0vgyuvH_vTgjDbBB8ps5WDST2oNwDLNRBGVuXqhvZAlLTWmfrvfVdOV5qyRsF3AOHR22FLWve6NwcYet45QvrSp4bBWlbiUbbihtYOtvWwCsJuvEwr2ujBe93J8rmG91DN85K1-6gg8BrK4yyXksF8w5idx7ukr0q10r2AphO-jfvr4OLghuvbn50GGzTp23yPFq9LV-S-WokWIxGYc7VDKF4yiIhaBShQhJKCJcYyygWDOOcTXMu45gwQiNKQiliJme8CFFOVTQdBuMTVjjrvVNFVjtdcnfMMMr65LM--ew3-c4Qnwwf2qjjP9dZsl4kf94vbySKeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Front Cover: Development of Fluorophosphoramidate as a Biocompatibly Transformable Functional Group and its Application as a Phosphate Prodrug for Nucleoside Analogs (ChemMedChem 17/2022)</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Yoshida, Yuki ; Zheng, Ti ; Tanabe, Wataru ; Tomoike, Fumiaki ; Hashiya, Fumitaka ; Suzuki, Tetsuro ; Hirota, Shuto ; Saiki, Yuriko ; Horii, Akira ; Hirayama, Akiyoshi ; Soga, Tomoyosi ; Kimura, Yasuaki ; Abe, Hiroshi</creator><creatorcontrib>Yoshida, Yuki ; Zheng, Ti ; Tanabe, Wataru ; Tomoike, Fumiaki ; Hashiya, Fumitaka ; Suzuki, Tetsuro ; Hirota, Shuto ; Saiki, Yuriko ; Horii, Akira ; Hirayama, Akiyoshi ; Soga, Tomoyosi ; Kimura, Yasuaki ; Abe, Hiroshi</creatorcontrib><description>The Front Cover shows a new type of biocompatible phosphate analog, a fluorophosphoramidate (FPA) functional group with characteristic P–F and P–N bonds. The stability of the FPA group was found to vary depending on the number of the amino group substitutions. Taking advantage of this intriguing molecular profile, gemcitabine FPA‐prodrug, which was designed to be efficiently converted to the corresponding monophosphate in cells, showed superior anticancer activity compared with the parent compound gemcitabine and its ProTide prodrug. More information can be found in the Research Article by Yuki Yoshida, Hiroshi Abe et al.</description><identifier>ISSN: 1860-7179</identifier><identifier>EISSN: 1860-7187</identifier><identifier>DOI: 10.1002/cmdc.202200450</identifier><language>eng</language><subject>anti-cancer drugs ; antiviral drugs ; nucleoside analogs ; phosphate ; prodrugs</subject><ispartof>ChemMedChem, 2022-09, Vol.17 (17), p.n/a</ispartof><rights>2022 Wiley‐VCH GmbH</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-0440-6820 ; 0000-0002-3967-3291 ; 0000-0002-0663-2792 ; 0000-0002-3754-789X ; 0000-0003-2724-2272 ; 0000-0003-0048-3789 ; 0000-0002-3609-602X ; 0000-0001-9502-2509</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Yoshida, Yuki</creatorcontrib><creatorcontrib>Zheng, Ti</creatorcontrib><creatorcontrib>Tanabe, Wataru</creatorcontrib><creatorcontrib>Tomoike, Fumiaki</creatorcontrib><creatorcontrib>Hashiya, Fumitaka</creatorcontrib><creatorcontrib>Suzuki, Tetsuro</creatorcontrib><creatorcontrib>Hirota, Shuto</creatorcontrib><creatorcontrib>Saiki, Yuriko</creatorcontrib><creatorcontrib>Horii, Akira</creatorcontrib><creatorcontrib>Hirayama, Akiyoshi</creatorcontrib><creatorcontrib>Soga, Tomoyosi</creatorcontrib><creatorcontrib>Kimura, Yasuaki</creatorcontrib><creatorcontrib>Abe, Hiroshi</creatorcontrib><title>Front Cover: Development of Fluorophosphoramidate as a Biocompatibly Transformable Functional Group and its Application as a Phosphate Prodrug for Nucleoside Analogs (ChemMedChem 17/2022)</title><title>ChemMedChem</title><description>The Front Cover shows a new type of biocompatible phosphate analog, a fluorophosphoramidate (FPA) functional group with characteristic P–F and P–N bonds. The stability of the FPA group was found to vary depending on the number of the amino group substitutions. Taking advantage of this intriguing molecular profile, gemcitabine FPA‐prodrug, which was designed to be efficiently converted to the corresponding monophosphate in cells, showed superior anticancer activity compared with the parent compound gemcitabine and its ProTide prodrug. More information can be found in the Research Article by Yuki Yoshida, Hiroshi Abe et al.</description><subject>anti-cancer drugs</subject><subject>antiviral drugs</subject><subject>nucleoside analogs</subject><subject>phosphate</subject><subject>prodrugs</subject><issn>1860-7179</issn><issn>1860-7187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkDFPwzAQhSMEEqWwMt8IQ1s7dWqHraSkILXQoXvk2E5r5MSRnRT1t_HnSCiCkeH0Tnf3PuleENxiNMYIhRNRSjEOURgiRCJ0Fgwwm6ERxYye__Y0vgyuvH_vTgjDbBB8ps5WDST2oNwDLNRBGVuXqhvZAlLTWmfrvfVdOV5qyRsF3AOHR22FLWve6NwcYet45QvrSp4bBWlbiUbbihtYOtvWwCsJuvEwr2ujBe93J8rmG91DN85K1-6gg8BrK4yyXksF8w5idx7ukr0q10r2AphO-jfvr4OLghuvbn50GGzTp23yPFq9LV-S-WokWIxGYc7VDKF4yiIhaBShQhJKCJcYyygWDOOcTXMu45gwQiNKQiliJme8CFFOVTQdBuMTVjjrvVNFVjtdcnfMMMr65LM--ew3-c4Qnwwf2qjjP9dZsl4kf94vbySKeg</recordid><startdate>20220905</startdate><enddate>20220905</enddate><creator>Yoshida, Yuki</creator><creator>Zheng, Ti</creator><creator>Tanabe, Wataru</creator><creator>Tomoike, Fumiaki</creator><creator>Hashiya, Fumitaka</creator><creator>Suzuki, Tetsuro</creator><creator>Hirota, Shuto</creator><creator>Saiki, Yuriko</creator><creator>Horii, Akira</creator><creator>Hirayama, Akiyoshi</creator><creator>Soga, Tomoyosi</creator><creator>Kimura, Yasuaki</creator><creator>Abe, Hiroshi</creator><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-0440-6820</orcidid><orcidid>https://orcid.org/0000-0002-3967-3291</orcidid><orcidid>https://orcid.org/0000-0002-0663-2792</orcidid><orcidid>https://orcid.org/0000-0002-3754-789X</orcidid><orcidid>https://orcid.org/0000-0003-2724-2272</orcidid><orcidid>https://orcid.org/0000-0003-0048-3789</orcidid><orcidid>https://orcid.org/0000-0002-3609-602X</orcidid><orcidid>https://orcid.org/0000-0001-9502-2509</orcidid></search><sort><creationdate>20220905</creationdate><title>Front Cover: Development of Fluorophosphoramidate as a Biocompatibly Transformable Functional Group and its Application as a Phosphate Prodrug for Nucleoside Analogs (ChemMedChem 17/2022)</title><author>Yoshida, Yuki ; Zheng, Ti ; Tanabe, Wataru ; Tomoike, Fumiaki ; Hashiya, Fumitaka ; Suzuki, Tetsuro ; Hirota, Shuto ; Saiki, Yuriko ; Horii, Akira ; Hirayama, Akiyoshi ; Soga, Tomoyosi ; Kimura, Yasuaki ; Abe, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c890-2bae6009385cc7550fd4744ad11d59c811b83bad9948475742dc98d6af20b7e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>anti-cancer drugs</topic><topic>antiviral drugs</topic><topic>nucleoside analogs</topic><topic>phosphate</topic><topic>prodrugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshida, Yuki</creatorcontrib><creatorcontrib>Zheng, Ti</creatorcontrib><creatorcontrib>Tanabe, Wataru</creatorcontrib><creatorcontrib>Tomoike, Fumiaki</creatorcontrib><creatorcontrib>Hashiya, Fumitaka</creatorcontrib><creatorcontrib>Suzuki, Tetsuro</creatorcontrib><creatorcontrib>Hirota, Shuto</creatorcontrib><creatorcontrib>Saiki, Yuriko</creatorcontrib><creatorcontrib>Horii, Akira</creatorcontrib><creatorcontrib>Hirayama, Akiyoshi</creatorcontrib><creatorcontrib>Soga, Tomoyosi</creatorcontrib><creatorcontrib>Kimura, Yasuaki</creatorcontrib><creatorcontrib>Abe, Hiroshi</creatorcontrib><collection>CrossRef</collection><jtitle>ChemMedChem</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshida, Yuki</au><au>Zheng, Ti</au><au>Tanabe, Wataru</au><au>Tomoike, Fumiaki</au><au>Hashiya, Fumitaka</au><au>Suzuki, Tetsuro</au><au>Hirota, Shuto</au><au>Saiki, Yuriko</au><au>Horii, Akira</au><au>Hirayama, Akiyoshi</au><au>Soga, Tomoyosi</au><au>Kimura, Yasuaki</au><au>Abe, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Front Cover: Development of Fluorophosphoramidate as a Biocompatibly Transformable Functional Group and its Application as a Phosphate Prodrug for Nucleoside Analogs (ChemMedChem 17/2022)</atitle><jtitle>ChemMedChem</jtitle><date>2022-09-05</date><risdate>2022</risdate><volume>17</volume><issue>17</issue><epage>n/a</epage><issn>1860-7179</issn><eissn>1860-7187</eissn><abstract>The Front Cover shows a new type of biocompatible phosphate analog, a fluorophosphoramidate (FPA) functional group with characteristic P–F and P–N bonds. The stability of the FPA group was found to vary depending on the number of the amino group substitutions. Taking advantage of this intriguing molecular profile, gemcitabine FPA‐prodrug, which was designed to be efficiently converted to the corresponding monophosphate in cells, showed superior anticancer activity compared with the parent compound gemcitabine and its ProTide prodrug. More information can be found in the Research Article by Yuki Yoshida, Hiroshi Abe et al.</abstract><doi>10.1002/cmdc.202200450</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0440-6820</orcidid><orcidid>https://orcid.org/0000-0002-3967-3291</orcidid><orcidid>https://orcid.org/0000-0002-0663-2792</orcidid><orcidid>https://orcid.org/0000-0002-3754-789X</orcidid><orcidid>https://orcid.org/0000-0003-2724-2272</orcidid><orcidid>https://orcid.org/0000-0003-0048-3789</orcidid><orcidid>https://orcid.org/0000-0002-3609-602X</orcidid><orcidid>https://orcid.org/0000-0001-9502-2509</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1860-7179
ispartof ChemMedChem, 2022-09, Vol.17 (17), p.n/a
issn 1860-7179
1860-7187
language eng
recordid cdi_crossref_primary_10_1002_cmdc_202200450
source Wiley-Blackwell Read & Publish Collection
subjects anti-cancer drugs
antiviral drugs
nucleoside analogs
phosphate
prodrugs
title Front Cover: Development of Fluorophosphoramidate as a Biocompatibly Transformable Functional Group and its Application as a Phosphate Prodrug for Nucleoside Analogs (ChemMedChem 17/2022)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A42%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Front%20Cover:%20Development%20of%20Fluorophosphoramidate%20as%20a%20Biocompatibly%20Transformable%20Functional%20Group%20and%20its%20Application%20as%20a%20Phosphate%20Prodrug%20for%20Nucleoside%20Analogs%20(ChemMedChem%2017/2022)&rft.jtitle=ChemMedChem&rft.au=Yoshida,%20Yuki&rft.date=2022-09-05&rft.volume=17&rft.issue=17&rft.epage=n/a&rft.issn=1860-7179&rft.eissn=1860-7187&rft_id=info:doi/10.1002/cmdc.202200450&rft_dat=%3Cwiley_cross%3ECMDC202200450%3C/wiley_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c890-2bae6009385cc7550fd4744ad11d59c811b83bad9948475742dc98d6af20b7e53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true